TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04305769: Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)

Sponsor: University of Virginia · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 260 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT04305769 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04305769 Rescue Dossier →